The Clinical, Economic, and Ethical Imperative for Public Subsidy of Palopegteriparatide (Yorvipath) in Australia

This report argues that the Australian Government’s refusal to subsidise Yorvipath (palopegteriparatide) represents a dangerous “false economy” that prioritises short-term pharmaceutical savings over the prevention of catastrophic long-term renal failure. By synthesizing clinical evidence from the Phase 3 PaTHway trial with Australian health expenditure data, the analysis demonstrates that the current “standard of care” is actively nephrotoxic, driving patients toward chronic kidney disease and dialysis costs exceeding $85,000 annually. The report concludes that the bureaucratic impasse cited by the PBAC—specifically regarding economic modeling horizons and local data gaps—is best resolved not by denial of care, but through a Managed Access Program (MAP) that grants immediate access to high-risk patients while collecting real-world data to validate the drug's long-term value.